Targeting extracellular glycans: Tuning multimeric boronic acids for pathogen-selective killing of Mycobacterium tuberculosis
Abstract
Innovative chemotherapeutic agents that are active against Mycobacterium tuberculosis (Mtb) are urgently required to control the tuberculosis (TB) epidemic. The Mtb cell envelope has distinct (lipo)polysaccharides and glycolipids that play a critical role in Mtb survival and pathogenesis and disruption of pathways involved in the assembly of the Mtb cell envelope are the primary target of anti-tubercular agents. Here we introduce a previously unexplored approach whereby chemical agents directly target the extracellular glycans within the unique Mtb cell envelope, rather than the intracellular biosynthetic machinery. We designed and synthesised multimeric boronic acids that are selectivity lethal to Mtb and function by targeting these structurally unique and essential Mtb cell envelope glycans. By tuning the number of, and distance between, boronic acid units high selectivity to Mtb, low cytotoxicity against mammalian cells and no observable resistance was achieved. This non-conventional approach may prevent the development of drug-resistance and will act as a platform for the design of improved, pathogen-specific, next generation antibiotics.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly.
A. B. Lanne, Y. Cui, … L. J. Alderwick·bioRxiv·Sep 3, 2020
- MTB-LysB1: A Novel Endolysin Against Multidrug-resistant Mycobacterium tuberculosis
Ritu Arora, Kandasamy Eniyan, … Urmi Bajpai·bioRxiv·Jul 13, 2026
- Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis
L. van Schie, K. Borgers, … N. Callewaert·bioRxiv·Apr 5, 2021
- Endolysin B: A new archetype in M. tuberculosis treatment
Anna Griego, Beatrice Antinori, … Loris Rizzello·bioRxiv·Dec 5, 2023
- Investigating β-lactam drug targets in Mycobacterium tuberculosis using chemical probes
K. E. Beatty, S. R. Levine·bioRxiv·Dec 19, 2019
- Comprehensive identification of β-lactam antibiotic polypharmacology in Mycobacterium tuberculosis
Kaylyn L. Devlin, Emily Hutchinson, … Kimberly E. Beatty·ACS Infectious DiseasesPeer-reviewed·Aug 18, 2025